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Alcohol intake has been associated to breast cancer in pre and postmenopausal women; however results are inconclusive regard-
ing tumor hormonal receptor status, and potential modifying factors like age at start drinking. Therefore, we investigated the rela-
tion between alcohol intake and the risk of breast cancer using prospective observational data from the European Prospective
Investigation into Cancer and Nutrition (EPIC). Up to 334,850 women, aged 35–70 years at baseline, were recruited in ten Euro-
pean countries and followed up an average of 11 years. Alcohol intake at baseline and average lifetime alcohol intake were calcu-
lated from country-specific dietary and lifestyle questionnaires. The study outcomes were the Hazard ratios (HR) of developing
breast cancer according to hormonal receptor status. During 3,670,439 person-years, 11,576 incident breast cancer cases were
diagnosed. Alcohol intake was significantly related to breast cancer risk, for each 10 g/day increase in alcohol intake the HR
increased by 4.2% (95% CI: 2.7–5.8%). Taking 0 to 5 g/day as reference, alcohol intake of >5 to 15 g/day was related to a 5.9%
increase in breast cancer risk (95% CI: 1–11%). Significant increasing trends were observed between alcohol intake and ER1/
PR1, ER2/PR2, HER22 and ER2/PR2HER22 tumors. Breast cancer risk was stronger among women who started drinking prior
to first full-time pregnancy. Overall, our results confirm the association between alcohol intake and both hormone receptor posi-
tive and hormone receptor negative breast tumors, suggesting that timing of exposure to alcohol drinking may affect the risk.
Therefore, women should be advised to control their alcohol consumption.
What’s new?
Although it is now established that alcohol consumption increases breast cancer risk, many questions remain. Using a pro-
spective study design with 11,576 incident breast cancer cases across 10 European countries, the authors confirmed the
increased risk of alcohol on breast cancer development. They further show that women who started drinking before their first
full-term pregnancy have a higher risk than women who started afterwards. These effects were observed in hormone-receptor
positive and –negative tumors pointing to non-hormonal pathways that need to be further investigated.
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A consistent association has been observed between alcohol
intake and breast cancer (BC) among both pre and post-
menopausal women,1 with a linear dose-response increase
ranging from 2%2 to 12%3 for each additional drink per day
(equivalent to about 10 g/day). While the association is ﬁrmly
established, some questions such as the association with spe-
ciﬁc tumor subtypes, the impact of the age at start drinking
and a potential window of susceptibility, remain unanswered.
Mechanistic evidences show that ethanol stimulates both cell
proliferation and estrogen receptor (ER) signaling in the
mammary gland.4–6 Most epidemiological studies report an
impact of ethanol on ER1 tumors.7 However a recent meta-
analysis showed an increased risk in both hormone receptor
positive and negative tumors.8 The consumption of alcoholic
beverages may interact with other BC risk factors such as
hormonal status or ﬁrst full-term pregnancy (FFTP),9,10and
thus differentially modulate breast cancer risk over a wom-
an’s lifetime.11 Recent studies report that low to moderate
alcohol intake between menarche and ﬁrst pregnancy is asso-
ciated with BC risk.12 It is, therefore, important to evaluate
the association of alcohol intake and BC phenotypes in light
of a potential modulating effect of age at start drinking.
Material and Methods
The European Prospective Investigation into Cancer and
Nutrition (EPIC) cohort consists of approximately 370,000
women and 150,000 men, aged 35–69, recruited between
1992 and 1998 in 23 research centers across 10 Western
European countries, Denmark (Aarhus and Copenhagen),
France, Germany (Heidelberg and Potsdam), Greece, Italy
(Florence, Varese, Ragusa, Turin, and Naples), Norway, Spain
(Asturias, Granada, Murcia, Navarra, and San Sebastian),
Sweden (Malm€o and Umeå), the Netherlands (Bilthoven and
Utrecht) and the United Kingdom (Cambridge and Oxford).
The design and methodology has been published elsewhere.13
Eligible men and women were invited to participate; those
who accepted gave informed consent and compiled question-
naires on diet, lifestyle, and medical history. EPIC recruited
367,993 women, aged 35–70 years. Women with prevalent
cancers at any site at recruitment (n5 19,853) or with miss-
ing diagnosis or censoring date (n5 2,892) were excluded. A
total of 3,339 subjects with missing dietary or lifestyle infor-
mation, and 6,753 women in the top and bottom 1% of the
ratio of energy intake to estimated energy requirement, calcu-
lated from age, sex, body weight and height, were excluded
from the analysis. In addition, 217 nonﬁrst breast cancer
cases were excluded. Thus, the analysis was performed in
334,850 EPIC women with complete exposure information.
Within this group, 11,576 women with invasive breast cancer
(including 1,227 carcinoma in situ) were identiﬁed after a
median follow-up of 11.0 years. Information on lifetime alco-
hol consumption was missing for Sweden, Norway, Naples
and Bilthoven, 24.1% were then excluded from the subanaly-
ses on lifetime alcohol intake. The study was approved by
IARC ethical committee and the local ethical committees of
the participating centers.
Dietary assessment, lifestyle and alcohol consumption
Dietary and lifestyle questionnaires were completed by partic-
ipants at enrolment when anthropometric measurements
were taken.13 Past-year physical activity (PA) in occupational
and recreational domains was assessed at baseline with a self-
administered questionnaire. For occupational activity, both
employment status as well as the level of physical activity
done during work was recorded as: nonworker, sedentary,
standing, manual, heavy manual and unknown (for which
duration and frequencies were not recorded). Recreational
time physical activity included walking, cycling and sport
activities. The duration and frequency of recreational activity
were multiplied by the intensity assigned by metabolic equiv-
alent values (METs) for the different activities. A total PA
index, the ‘‘Cambridge PA Index’’ was estimated by crossta-
bulating occupational with recreational PA. This index is
based on occupational, cycling and sport activities.
Information on alcohol use at the time of enrolment into
the study was based on a dietary assessment of usual consump-
tion of alcoholic beverages and types of alcoholic beverage (i.e.,
wine, beer, spirits and liquors) during the past 12 months. In
each country, intake was calculated based on the estimated
average glass volume and ethanol content for each type of alco-
holic beverage, using information collected in highly standar-
dized 24-hr dietary recalls from a subset of the cohort.14
Information on past alcohol consumption (available for 75.9%
of participants) was assessed as glasses of different beverages
consumed per week at 20, 30, 40 and 50 years of age. Average
lifetime alcohol intake was determined as a weighted average
of intake at different ages, with weights equal to the time of
individual exposure to alcohol at different ages. To determine
which women had started drinking prior to FFTP, we used
information on alcohol consumption at different ages and the
age of FFTP reported by the women in the questionnaire.
Anthropometric measurements
Weight and height were measured at baseline, while the sub-
jects were not wearing shoes, to the nearest 0.1 kg, or to the
nearest 0.1, 0.5 or 1.0 cm, depending on the center.15 In
France, Norway and Oxford, height and weight were self-
reported on a questionnaire. The procedures used to account
for procedural differences between centers in the collection of
anthropometric measurements are described elsewhere.16
Perspective ascertainment of breast cancer cases, coding
of receptor status and determination of menopausal status
Incident BC cases were identiﬁed through population cancer
registries (Denmark, Italy, the Netherlands, Norway, Spain,
Sweden and United Kingdom) or by active follow-up (France,
Germany, Naples and Greece). The active follow-up proce-
dure used a combination of methods, including health insur-
ance records, cancer and pathology registries and contacts
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with participants and their next-of-kin. Subjects were fol-
lowed up from study entry and until cancer diagnosis (except
for nonmelanoma skin cancer cases), death and emigration
or until the end of the follow-up period, whichever occurred
ﬁrst. The end of follow-up period was: December 2004 (Astu-
rias), December 2006 (Florence, Varese, Ragusa, Granada and
San Sebastian), December 2007 (Murcia, Navarra, Oxford,
Bilthoven, Utrecht and Denmark), June 2008 (Cambridge),
December 2008 (Turin, Malmo, Umea and Norway). For
study centers with active follow-up, the last follow-up contact
was: December 2006 for France, December 2009 for Greece,
June 2010 for Heidelberg, December 2008 for Potsdam and
December 2006 for Naples. Cancer incidence data were clas-
siﬁed according to the International Classiﬁcation of Diseases
for Oncology, Second Revision (ICDO-2).
Information on tumor receptor status, on the available lab-
oratory methods and on quantiﬁcation descriptions used to
determine receptor status, were collected by 20 centers. Infor-
mation on ER, progesterone receptor (PR) and human epider-
mal growth factor receptor 2 (HER2) was provided by each
center based on pathology reports. To standardize the quanti-
ﬁcation of receptor status among the EPIC centers, the follow-
ing criteria for a positive receptor status were used: 10%
cells stained, any “plus-system” description, 20 fmol/mg, an
Allred score of 3, an IRS 2 or an H-score 10.17–21
Women were considered as premenopausal when report-
ing regular menses over the past 12 months, or when aged
<46 years at recruitment. Women were considered as post-
menopausal when not reporting any menses over the past 12
months, or having received bilateral ovariectomy. Women
with missing or incomplete questionnaire data or with previ-
ous hysterectomy, were considered postmenopausal only if
older than 55 years of age. Women were considered with
unknown menopausal status when aged between 46 and 55
years and had missing or incomplete questionnaire data, or
reported previous hysterectomy (without ovariectomy).22,23
Statistical analysis
Cox proportional hazards regression models were used to
quantify the association between alcohol consumption and
breast cancer risk. Age was the primary time variable and the
Breslow method was adopted for handling ties.24 Time at
entry was age at recruitment; time at exit was age at cancer
diagnosis, death, loss to follow-up, or end of follow-up,
whichever came ﬁrst. Models were stratiﬁed by center to con-
trol for differences in questionnaire design, follow-up proce-
dures and other center effects. Further stratiﬁcation by age at
recruitment (1-year categories) was used. Systematic adjust-
ments were made for menopausal status (dichotomized as
postmenopausal or women that underwent an ovariectomy
vs. other), weight and height (all continuous), smoking
(never, former, and current), educational attainment (ﬁve cat-
egories of schooling) as a proxy variable for socioeconomic
status, physical activity (inactive, moderately inactive, moder-
ately active, active). In addition, the following variables were
included in the models: age at menarche (12, 12–14, >14
years), age at birth of ﬁrst child (nulliparous, 21, 21–30,
>30 years), and age at menopause (50, >50 years), ever
use of contraceptive pill and ever use of replacement hor-
mones, energy intake without alcohol consumption and
adjustment for interaction “menopause, weight.”
Alcohol consumption was modeled as both continuous
and categorical variable (none, 0.1–5, 5.1–15, 15.1–30, >30 g/
day). Both baseline consumption and lifetime consumption
were studied. Correlation between both estimations was high
(r5 0.80). P-trend values were obtained by modeling a score
variable (from 1 to 5) category-speciﬁc level of alcohol at
baseline. In addition, the shape of the dose-response curve
between alcohol consumption and breast cancer risk was
evaluated with fractional polynomials of order two,25 using
3 g/day as reference value and after exclusion of former con-
sumers at baseline. Nonlinearity was tested comparing the
difference in log-likelihood of a model with fractional poly-
nomials with a model with a linear term only to a chi-square
distribution with three degrees of freedom.25 For all models,
the proportional hazards assumption was satisﬁed, evaluated
via inclusion into the disease model of interaction terms
between exposure and attained age (data not shown). Statisti-
cal heterogeneity of associations across countries or receptor
status, was based on a v2 statistics, computed comparing
country-speciﬁc coefﬁcients to an overall coefﬁcient. Stratiﬁed
analyses were conducted according to the time at start drink-
ing (prior of after FFTP) and interaction term was tested
using alcohol intake as continuous variable in multivariate
models. Models were run with the exclusion of the ﬁrst 2
years of follow-up, but the results did not differ from those
including the entire cohort (data not shown).
Statistical tests were two sided, and p-values <0.05 were
considered signiﬁcant. All analyses were performed using
SAS version 9.2 (SAS Institute, 1999) and STATA (Stata Sta-
tistical Software: Release 12 (2011) StataCorp.,College Station,
TX: StataCorp LP).
Results
During an average of 11.0 years of follow-up (3,670,43940
person-years) of 334,850 study participants, the EPIC study
documented 11,576 incident BC cases (e-Table 1). The over-
all percentage of women drinking over 15 g/day at baseline
was 16.3% (e-Table 1).
The mean age at recruitment was 50.8 years, and the
mean age at BC diagnosis was 59.4 years. Table 1 presents
the baseline alcohol intake according to the distribution of
major baseline demographic and lifestyle characteristics. At
baseline, 35.2% of women were premenopausal and 43.1%
postmenopausal (the menopausal status of 18.8% of women
was not deﬁned, and 2.9% reported bilateral ovariectomy;
Table 1). No drinkers at baseline were less likely to ever have
used exogenous hormones and less likely to have ever
smoked, were more moderately active and attained less edu-
cation at baseline than drinkers at baseline (Table 1).
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Alcohol intake showed a signiﬁcant positive dose-response
relation with BC (p< 0.0001, Table 2). BC hazard ratio (HR)
was increased by 6% (95% CI: 1–11%), 12% (95% CI: 6–
19%) and 25% (95% CI: 17–35%) for the consumption of 5–
15 g/day, 15–30 g/day and >30 g/day, respectively, compared
to the 0.1–5 g/day category of intake. For each additional
10 g/day the HR increased by 4% (95% CI: 3–6%). Figure 1
shows the relation between alcohol intake and BC risk, frac-
tional polynomial of order 2 using 3 g/day as reference. A
statistically signiﬁcant relation was observed (p< 0.0001),
while the test for nonlinearity was compatible with a linear
trend (p5 0.100).
When the associations were evaluated according to hor-
mone receptor status, for each additional 10 g/day the HR
signiﬁcantly increased by 4% (95% CI: 1–6%) in ER1/PR1,
by 5% (95% CI: 0–10%) in ER2/PR2, by 5% (95% CI: 2–
9%) in HER22 and by 12% (95% CI: 3–23%) in ER2/PR2/
HER22 breast tumors (Table 2). Test for heterogeneity
between alcohol consumption and hormone receptor status
was not signiﬁcant (p5 0.26). No signiﬁcant association was
observed for ER1/PR2, ER2/PR1 and HER21. When
using lifetime alcohol intake slightly lower estimates were
observed (see eTable2). Similar results were observed for pre
and postmenopausal women, although, given the smaller
sample size among premenopausal women, statistically signif-
icance was reached only in the overall analysis. There was no
heterogeneity in results between pre and postmenopausal
women (p interaction5 0.48). No interaction was observed
with body mass index (BMI) or use of exogenous hormones
either. Since statistical adjustment for smoking can be difﬁ-
cult, analyses in nonsmokers at baseline were carried out and
results remained virtually similar (data not shown).
Age at start drinking according to FFTP, was positively
related to BC risk among women who start drinking prior to
FFTP. Stronger associations were observed for ER2, PR2,
ER2/PR2 and ER2/PR2/HER22 tumors (Table 3). In a
multivariable model, an increase of 10 g of alcohol/day was
related to an 8% (95% CI: 2–14%) increased risk of ER2
tumors in women who start drinking prior to FFTP, while no
association could be detected among women who start drink-
ing after FFTP (p for interaction5 0.047), and a 9% (95% CI:
2–16%) increased risk of ER2/PR2 tumors in women who
start drinking prior to FFTP (p for interaction5 0.10). When
using lifetime alcohol intake slightly lower estimates were
observed (see eTable3). We were not able to evaluate the
amount of alcohol consumed prior to FFTP.
BC hazard ratios, with data stratiﬁed according to the
median period between menarche and FFTP (13 years)
among women who start drinking prior to FFTP, was of
5.6% (95% CI: 2.6–8.8%) among women with longer median
period and of 2.6% (95% CI: 1.0–6.2%) among their counter-
part. These data suggest that a longer time between menarche
and FFTP may modulate BC risk among women who start
drinking prior to FFTP. However, the test for interaction was
not signiﬁcant (p5 0.23) (data not shown).
Discussion
In this prospective study of 334,850 women and 11,576 inci-
dent BC cases, an increased intake of 10 g of alcohol/day was
related to a 4.2% increased BC risk (95% CI: 2.7–5.8%). This
was observed for both ER1/PR1 and ER2/PR2 tumor sub-
types with the largest risk observed for triple negative tumors
(ER2/PR2/HER22). No interaction was observed with BMI
and use of hormones. Women who started drinking before
their FFTP appeared to be at higher risk for BC than women
who started drinking after their FFTP.
Most studies published to date have reported an increased
BC risk with increasing alcohol intake.1 A previous analysis
within the EPIC cohort on a smaller number of BC cases
(n5 4,285), reported a 3% increase in BC incidence for each
additional 10 g/day of alcohol.26 Our results, based on
[mt]11,000 incident BC cases, conﬁrm our previous results
and suggest a slightly stronger association. We did not observe
strong differences in estimates across tumor receptor status
(triple negative tumors showed the strongest risk, however, the
sample size in this category was small). Although most of prior
studies have reported a higher risk for ER1 and/or PR1
tumors compared to ER2 and/or PR2 tumors in particular,
for the highest versus the lowest alcohol intake group,9,27–33 an
increased risk for hormone receptor negative tumors was also
reported.8,34,35 This inconsistency of results across studies
might be partially due to the smaller number of BC cases with
negative hormone receptor status. The very large number of
both hormone receptor positive and hormone receptor nega-
tive tumors in our study increased our power on the associa-
tion. Nonhormonal pathways such as DNA damage are likely
to be involved in the incidence of receptor negative tumors.8
The effect of alcohol appears linear, suggesting that there is no
safe level of intake for BC risk.
A limited number of studies have investigated the pres-
ence of a window of susceptibility to alcohol carcinogenesis
in the breast. Some epidemiological studies suggest that
drinking alcohol during adolescence or early adulthood has a
strong impact on BC risk.36 Results from the Nurses’ Health
Study II show that low to moderate alcohol intake during
adolescence and early adulthood is dose-dependently associ-
ated with an increased risk of proliferative benign breast dis-
ease, which may lead to invasive BC later in life.37 More
recent results support the effect of drinking alcohol between
menarche and FFTP on BC risk (RR5 1.11 per 10 g/day
intake; 95% CI: 1.00–1.23) and on proliferative benign breast
disease (RR5 1.16 per 10 g/day intake; 95% CI: 1–1.02).11 In
addition, the association between drinking before FFTP and
development of breast neoplasia appeared to be stronger with
longer menarche to ﬁrst pregnancy intervals. These results
are consistent with the hypothesis that alcohol carcinogens
may preferentially act during mammary development.38 We
observed a stronger effect of alcohol intake prior to FFTP,
with a signiﬁcant interaction for receptor negative tumors.
Our ﬁndings suggest that starting drinking before FFTP might
be a more sensitive period, even if we cannot exclude the
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possibility that the stronger association between alcohol intake
and BC in women who started drinking before FFTP might be
the consequence of longer duration and amount of drinking.
In our study, demographic characteristic, lifestyle and
alcohol intake of women with available hormone receptor
status could have differed from women with unavailable sta-
tus. However, we did not observe such differences among
cases with known and unknown ER status and sub analyses
of these groups led to similar overall results. Similar strategies
were adopted to inspect BC cases with and without available
information on PR and HER2 status. In addition, a bias due
to the inﬂuence of preclinical disease on alcohol intake is
unlikely, given that similar results were obtained after exclu-
sion of samples from the ﬁrst 2 years of follow-up. However,
we conducted multiple comparison analyses based on hormo-
nal status and chance ﬁndings cannot be excluded.
Major strengths of our study include the prospective and
population based design, the large sample size, detailed infor-
mation on alcohol intake at different period of life, age at
start drinking and types of beverage, data on hormone recep-
tor status, excellent follow-up and large number of cases,
which provided us with good power for subgroups analyses.
Information on alcohol intake was self-reported and potential
misclassiﬁcation may have underestimated the effect of alco-
hol intake. Still, assessment of alcohol intake has been shown
to be reliable in the EPIC cohort39,40 and the prospective set-
ting of our study minimizes recall bias on age at start drink-
ing and lifetime alcohol intake. We were unable to determine
the amount of alcohol consumed before FTTP and while
consumption both at baseline and over lifetime was
Table 3. Breast cancer risk among parous women with alcohol intake at baseline by age at start drinking before/after first full-term
pregnancy
Average daily alcohol intake at baseline
Age at start
drinking N cases/person-years HR (95% CI) for 10 g/day p-value
Interaction
p-value1
All cases Before FFTP 4,104/1,216,204 1.04 (1.02–1.06) .001 0.14
After FFTP 2,747/793,546 1.02 (0.99–1.05) 0.26
ER1 Before FFTP 2,221/1,205,111 1.04 (1.01–1.07) 0.005 0.16
After FFTP 1,460/786,197 1.02 (0.98–1.07) 0.32
PR1 Before FFTP 1,375/1,199,890 1.04 (0.99–1.07) 0.06 0.40
After FFTP 987/783,211 1.01 (0.96–1.07) 0.60
ER1/PR1 Before FFTP 1,286/1,199,505 1.04 (1.00–1.08) 0.04 0.39
After FFTP 924/782,918 1.01 (0.96–1.07) 0.65
ER2 Before FFTP 552/1,194,218 1.08 (1.02–1.14) 0.009 0.05
After FFTP 371/778,873 0.97 (0.88–1.06) 0.49
PR2 Before FFTP 776/1,196,034 1.06 (1.02–1.11) 0.009 0.05
After FFTP 545/780,237 0.98 (0.91–1.06) 0.66
ER2/PR2 Before FFTP 383/1,193,437 1.09 (1.02–1.16) 0.01 0.10
After FFTP 261/778,358 0.97 (0.88–1.09) 0.65
ER2/PR2/HER22 Before FFTP 99/1,191,822 1.17 (1.04–1.31) 0.007 0.24
After FFTP 50/777,139 0.97 (0.75–1.24) 0.78
1Age start prior to first full-term pregnancy (FFTP), was defined based on the information on ‘Age at start drinking alcohol’ and ‘Age at first full-term
pregnancy’. Results of stratified analyses by age start prior/after FFTP are displayed. Significance of interaction term was tested including in a multi-
variate model using alcohol as continuous variable and age start prior/after FFTP as categorical variable.
Note: Adjustments are the same as in Table 2. The statistical significance of interactions was assessed using likelihood ratio tests based on the
models with and without the interaction terms formed by the product of age at start drinking alcohol before or after first pregnancy and the value of
alcohol intake at recruitment.
Figure 1. – Dose-response curve of BC risk with alcohol intake at
recruitment. The dose-response curve is displayed up to 35 g/day,
corresponding to the 99th percentile of the alcohol intake distribu-
tion. [Color figure can be viewed in the online issue, which is avail-
able at wileyonlinelibrary.com.]
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associated with a stronger adverse effect among women who
start drinking prior to FFTP than among their counterpart,
our results should be interpreted with caution.
In conclusion, ﬁndings from the EPIC cohort conﬁrm the
carcinogenic effect of alcohol intake on both receptor posi-
tive and negative breast tumors. Starting to drink prior to
FFTP appears to have a larger adverse effect than after
FTTP. No interaction with body fatness and use of hormone
was observed. Alcohol has been shown to act through the
estrogen pathway, however our results suggest that nonhor-
monal pathways are likely to act and need to be further
investigated.
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